Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 14/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794426 | 1.00 | HCRTR2 (0.49) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 | |
| SCHEMBL600759 | 0.92 | HCRTR2 (0.49) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 | |
| SCHEMBL601360 | 0.87 | HCRTR1 (0.49) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 | |
| SCHEMBL599430 | 0.87 | HCRTR1 (0.49) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 | |
| SCHEMBL30795402 | 0.86 | HCRTR1 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL600480 | 0.86 | HCRTR1 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL600403 | 0.82 | HCRTR1 (0.45) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 | |
| SCHEMBL599265 | 0.82 | HCRTR1 (0.44) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 | |
| SCHEMBL601294 | 0.82 | HCRTR1 (0.44) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 | |
| SCHEMBL599923 | 0.82 | HCRTR1 (0.46) | HCRTR2HCRTR1CYP1A2CYP2C9TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421370-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-02-29 | — | — | EP | claimed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | claimed |
| WO-2010124055-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010124055-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | GRM5, GRIK5, GRM2 | HCRTR2 102/4885HCRTR1 199/4885CYP1A2 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.